Jane Street
GEVA

Jane Street’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Jane Street’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,567
Closed -$378K – 3496
2014
Q1 		$378K Buy
+4,567
New +$422K ﹤0.01% 1799
2013
Q3 		– Sell
-9,940
Closed -$417K – 3477
2013
Q2 		$417K Buy
+9,940
New +$453K 0.01% 1593

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jane Street's GEVA Position: Q2 2014 in Review

Jane Street sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2014, closing a stake of 4,567 shares — an estimated $378K sold.

Jane Street first reported a position in GEVA in Q2 2013 and held it in 2 quarters. The position peaked at $417K in Q2 2013. 115 funds tracked by Wall St. Rank hold GEVA as of Q2 2014.

  • Jane Street reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2014 after selling out during the quarter.
  • Jane Street sold 4,567 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2014, an estimated $378K.
  • Jane Street first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 2 quarters.
  • Jane Street's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $417K in Q2 2013.
  • 115 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2014.

Based on Jane Street's 13F filing for Q2 2014, filed 14 Aug 2014.